Compare
Artelo Biosciences, Inc. vs BullFrog AI Holdings, Inc. vs Neonc Technologies Holdings, Inc. vs Lipella Pharmaceuticals Inc.
| Latest fiscal year | Artelo Biosciences, Inc. ARTL | BullFrog AI Holdings, Inc. BFRG | Neonc Technologies Holdings, Inc. NTHI | Lipella Pharmaceuticals Inc. LIPOLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | $116.7K | $40.0K | $536.4K |
| Revenue growth (YoY) | n/a | n/a | -51.8% | +19.3% |
| Gross margin | n/a | 18.8% | n/a | n/a |
| Operating margin | n/a | n/m | n/m | -947.2% |
| Net margin | n/a | n/m | n/m | -935.2% |
| Net income | -$12.88M | -$6.50M | -$62.15M | -$5.02M |
| EPS (Diluted) | -$12.52 | -$0.63 | -$3.20 | -$4.79 |
| Operating cash flow | -$8.52M | -$5.52M | -$20.36M | -$3.95M |
| Free cash flow | n/a | n/a | -$20.86M | n/a |
| Cash & equivalents | $600.0K | $2.18M | $58.7K | $2.18M |
| Total assets | $2.80M | $2.81M | $2.82M | $2.67M |
| Total liabilities | $4.07M | $672.0K | $20.33M | $754.4K |
| Shareholders' equity | -$1.27M | $2.14M | -$17.51M | $1.92M |
| Return on year-end equity | n/a | -304.2% | n/a | -261.3% |
| Shares outstanding | 2.02M | 11.42M | 21.99M | 1.21M |
Revenue, most recent five fiscal years
| Fiscal year | Artelo Biosciences, Inc. | BullFrog AI Holdings, Inc. | Neonc Technologies Holdings, Inc. | Lipella Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | n/a | $116.7K Ended 2025-12-31 | $40.0K Ended 2025-12-31 | $536.4K Ended 2024-12-31 |
| 1 year earlier | n/a | n/a | $83.0K Ended 2024-12-31 | $449.6K Ended 2023-12-31 |
| 2 years earlier | n/a | $65.0K Ended 2023-12-31 | n/a | $184.2K Ended 2022-12-31 |
| 3 years earlier | n/a | $10.0K Ended 2022-12-31 | n/a | $259.3K Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |